John Theurer Cancer Center Opens New Comprehensive Facility

Publication
Article
Oncology Nursing NewsDecember 2010
Volume 4
Issue 6

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States, recently opened a new $130-million, 155,000-square-foot comprehensive cancer facility. “This new facility will help us build on our promise to deliver extraordinary care by providing patients with an unparalleled experience through innovative approaches in comfortable surroundings,” said Andrew L. Pecora, MD, FACP, CPE, chief innovations officer and professor and vice president of cancer services, JTCC.

Articles in this issue
Net Guides: Melanoma
Net Guides: Bone Metastases
Yoga for Cancer Care
FDA Updates
The Future of Nursing
Net Guides: Liver Cancer
Net Guides: Carcinoma of Unknown Primary Orgin
Tools to Help Patients Navigate Their Treatment Path
John Theurer Cancer Center Opens New Comprehensive Facility
Bone Loss Drugs Increase Stroke Risk in Patients With Cancer
Oncology Community Facing Severe Drug Shortages
Net Guides: Oral Cancer

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
a man wearing a suit and tie in front of a green screen with the ONN logo
Elizabeth Burton in an interview with Oncology Nursing News
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content
Graphic image of a blue brain on a blue background

Breakthrough Designation Granted to BCB-276 for Pediatric DIPG

Chris Ryan
April 25th 2025
Article

Findings from the phase 1 BrainChild-03 trial support breakthrough designation for BCB-276 for pediatric diffuse intrinsic pontine glioma.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Line illustration of red blood cells on a yellow background

Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

Russ Conroy
April 20th 2025
Article

Using tools like the ICE Score could improve consistency in grading neurotoxicity tied to bispecific antibodies in hematologic cancers.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Graphic reading "FDA Approved" resembling a stamp of approval

FDA Approves Larotrectinib for NTRK Fusion-Positive Solid Tumors

Bridget Hoyt
April 10th 2025
Article

The FDA approved larotrectinib for use in adult and pediatric patients with NTRK fusion-positive solid tumors with few other options.

Image of a row of vials lined up on a counter

VXM01 Vaccine/Avelumab Displays Safety, Early Clinical Activity in GBM

Ashling Wahner
April 8th 2025
Article

VXM01 plus avelumab was tolerable and could potentially produce clinically meaningful responses in patients with recurrent glioblastoma.